For research use only. Not for therapeutic Use.
K22 is an inhibitor of coronavirus replication that specifically interferes with membrane-bound coronaviral RNA synthesis (IC50 value of 0.7 µM for HCoV-229E plaques). K22 displayed antiviral activity against a broad range of animal and human coronaviruses, including MERS-CoV.
KEYWORDS: K22 | Supplier | Coronavirus inhibitor | ZIKV inhibitor K22 | K 22 | K-22 | CAS [2141978-86-9] | RNA | Virus | Inhibitor | Middle East respiratory syndrome
| Catalog Number | I038696 |
| CAS Number | 2141978-86-9 |
| Molecular Formula | C27H25BrN2O3 |
| Purity | ≥95% |
| IUPAC Name | N-[(Z)-3-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-3-oxo-1-phenylprop-1-en-2-yl]benzamide |
| InChI | InChI=1S/C27H25BrN2O3/c28-23-13-11-22(12-14-23)27(33)15-17-30(18-16-27)26(32)24(19-20-7-3-1-4-8-20)29-25(31)21-9-5-2-6-10-21/h1-14,19,33H,15-18H2,(H,29,31)/b24-19- |
| SMILES | C1CN(CCC1(C2=CC=C(C=C2)Br)O)C(=O)/C(=C/C3=CC=CC=C3)/NC(=O)C4=CC=CC=C4 |
| Reference | A Lundin et al. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus. PLoS Pathog. 2014 May 29;10(5):e1004166. O García-Nicolás et al. The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01206-18. |
